December 17, 2024 08:00 ET Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall Survival Doubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in Median Overall Survival Multiple Patients with Complete Responses (CRs) and/or Partial Response (PR) with 100% Reduction in […]
November 26, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000® Index as part
Actuate Therapeutics to be Added to Russell 2000® Index Read More »
November 12, 2024 08:00 ET Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and Adolescents Ongoing Enrollment in Phase 1/2 Trial of Elraglusib in Relapsed/Refractory Ewing Sarcoma with Topline Phase 1 Data Expected in 2H 2025 Rare Pediatric Disease Designation Provides Eligibility for Elraglusib
October 29, 2024 18:39 ET Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development Read More »
September 23, 2024 08:00 ET New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of Neuroblastoma Study Illustrates Potential to Activate the Immune System Even in Cancers That Have Not Previously Responded to Checkpoint Inhibitors CHICAGO and FORT WORTH, Texas, Sept. 23, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics,
September 16, 2024 08:00 ET Preclinical Study Highlight the Potential of Elraglusib in Overcoming FOLFIRINOX-induced Chemoresistance Through Downregulation of Epithelial to Mesenchymal Transition (EMT) Initial Data Demonstrates Early Evidence of Increased Clinical Activity of Combining FOLFIRINOX with Elraglusib and Losartan in Patients with Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Deep, Durable Responses Observed in 3/6
September 11, 2024 08:00 ET Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc.
